Chavez Margarita 4

What Happened

• Margarita Chavez, a director of Aligos Therapeutics (ALGS), was granted a derivative award on 2026-06-25 covering 5,860 shares. The reported transaction shows an acquisition of 5,860 shares at $0.00 (total $0), identified as a derivative (option) grant rather than a market purchase or sale.
• The award will vest and become exercisable 100% on the earlier of the first anniversary of the grant date or immediately prior to the issuer’s 2027 annual meeting, subject to continuous service.

Key Details

• Transaction date: 2026-06-25; Form 4 filed: 2026-06-29 (filed within required reporting window).
• Grant type: Derivative/option (code A — award/grant); reported price: $0.00 per share; reported value: $0.
• Vesting: 100% on earlier of one-year anniversary or just before 2027 annual meeting (subject to continued service).
• Shares owned after transaction: not specified in the filing.
• No tax-withholding, sale, or exercise reported in this filing.

Context

• This was a compensation award (option grant) to a director, not a purchase or sale. Such grants are common for board compensation and do not by themselves indicate buying/selling sentiment.
• The option is not reported as exercised or sold; it becomes exercisable upon vesting per the disclosed schedule.